A Novel Functional In Vitro Model that Recapitulates Human Muscle Disorders by Toral-Ojeda, Iván et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






A Novel Functional In Vitro Model that Recapitulates
Human Muscle Disorders
Iván Toral-Ojeda, Garazi Aldanondo,
Jaione Lasa-Elgarresta, Haizpea Lasa-Fernandez,
Camila Vesga-Castro, Vincent Mouly,
Adolfo López de Munain and
Ainara Vallejo-Illarramendi
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.75903
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original work is properly cited. 
Iván Toral- jeda, arazi  ldanondo, 
Jai  Lasa-El arr sta, aiz a Lasa-F r a z, 
il   s - str , i t  l , 
l     i   
 
iti l i f r ti  is v il l  t t   f t  c t r
Abstract
Here, we aim to address the increasing need for a suitable human muscle in vitro model 
in order to advance in the knowledge of muscle pathophysiology and test novel thera-
pies for muscle disorders. Our model is based on a simple 2D culture method that yields 
highly mature human myotubes under optimized environmental conditions. Culture 
conditions that produced functional and contractile human myotubes with an extended 
lifetime consisted in extracellular matrix overlay and addition of several trophic factors 
to the differentiation medium. In this work, we describe the generation of suitable mod-
els of muscular dystrophies (limb-girdle muscular dystrophy type 2A—LGMD2A and 
Duchenne) by silencing expression of key proteins in these myotubes. Western blot and 
immunocytochemical analyses demonstrated similar features between our knockdown 
human myotubes and dystrophic muscles in vivo, which support the general validity 
of our cellular models. We also found that both dystrophic models present higher rest-
ing cytosolic Ca2+ levels than controls, which support a common underlying deficit in 
calcium homeostasis. This novel human in vitro system would allow for high-throughput 
screening of new treatments for these muscular dystrophies as well as for other neuro-
muscular disorders. In addition, our model could be used to advance in our understand-
ing of human skeletal muscle pathophysiology.
Keywords: human muscle model, LHCN-M2 cell line, calpain 3, dystrophin, myotube 
maturation, muscular dystrophy
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1. Introduction
Skeletal muscle comprises around 40% of the total body mass in adults, and it is composed 
of contractile multinucleated myofibers formed by the fusion of myoblasts. Muscle fibers are 
coated by an extracellular matrix (ECM), namely the basement membrane, which accounts for 
around 5% of the skeletal muscle mass. This matrix provides mechanical structure to myofi-
bers during contractions, contributes elastic properties to the tissue, and partakes in the trans-
mission of force from the myofiber to the tendon. It is well known that muscle homeostasis 
relies on the relation between the different cell types present in the muscle tissue and their 
microenvironment. Thus, communication between the ECM and muscle cells is essential for 
gene expression, cell proliferation, adhesion, and differentiation [1].
One of the in vitro systems most widely used to study muscle pathophysiology is the mouse 
myoblast culture, which differentiates into mature myotubes with spontaneous contractile 
capacity within 6–14 days [2, 3]. In contrast, human skeletal myotubes display lower matura-
tion and survival capacity with reduced sarcomeric cross-striation, and they generally lack 
contractile capacity [4, 5]. Moreover, human myotubes display a high inter-individual hetero-
geneity with regard to myotube morphology, survival, and differentiation [6], which makes 
comparisons between healthy and diseased myotubes challenging. Furthermore, sample 
availability is a substantial limiting factor due to scarcity of muscle biopsies and limited pro-
liferation of human myoblasts, particularly when isolated from dystrophic muscles [7].
On the other hand, in vivo mouse models do not often reproduce the severity of human 
disorders, probably due to a reduced regeneration capacity of human muscles compared to 
mice [8]. Also, different underlying pathophysiological mechanisms in humans and mice can-
not be ruled out and, thus, therapies tested on mouse models may not necessarily yield the 
same results in human patients [9]. For instance, cerivastatin was released to the market as it 
was well tolerated in several animal models but caused fatal rhabdomyolysis in humans [10]. 
Therefore, it is becoming essential to generate a well-characterized and reproducible human 
in vitro model of skeletal muscle with pathophysiological relevance to human muscle diseases 
in order to advance in the generation of specific therapies.
Previous attempts in this line have been focused on promoting contractility of human myo-
tubes, in order to increase maturation and mimic exercise and adaptive responses character-
istic of skeletal muscle. Different strategies include exogenous application of electrical pulse 
stimulation to cultured myotubes [11–15], magnetic fields to induce myoblast differentiation, 
and co-culturing with spinal cord explants [16–19] or human motoneurons [20, 21] in order to 
achieve myotube innervation and subsequent maturation. More recently, spontaneous con-
tractile activity has been observed in human myotubes by using a defined differentiation 
medium containing several trophic factors [22]. Other works have achieved improvement of 
survival, maturity, and attachment of human myotubes by modifying the extracellular micro-
environment through addition of polymeric coatings or micro-patterned surfaces [23–27].
As an alternative, several studies on neuromuscular disorders are based on myotubes 
obtained from sources other than muscle biopsies, such as MyoD-converted fibroblasts 
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[28, 29] or, more recently, human-inducible stem cells (induced pluripotent stem cells—iPSCs) 
derived to myoblasts [30, 31]. More recently, significant progress has been made toward engi-
neering functional 3D human muscle systems using iPSCs [32, 33]. While these models over-
come limitations regarding sample availability and they have demonstrated physiological 
relevance to humans, still they require special handling and significant resources in terms of 
costs and time. Immortalization of primary myoblasts from dystrophic patients seems to be 
a reasonable compromise among sample availability, relevance to human muscle, and cost-
effectiveness [34].
In this chapter, we sought to generate a functional 2D human in vitro model of skeletal mus-
cle. For this purpose, we have used the immortalized LHCN-M2 myogenic cell line that was 
obtained from the skeletal muscle of a healthy male donor [35]. This human myoblast cell line 
was selected due to its thorough characterization and availability to the scientific community 
and because it displays relatively high differentiation levels compared to other human cell 
lines. Thus, we thoroughly optimized culture conditions in order to obtain highly mature 
human myotubes with distinct sarcomeric patterning and spontaneous contractility. Then, 
we validated its relevance for the study of muscular dystrophies by silencing expression of 
dystrophin and calpain 3 proteins. We used shRNA-lentiviral infection to silence expres-
sion of dystrophin and calpain 3 proteins, whose deficiency causes Duchenne and LGMD2A 
muscular dystrophies, respectively. Relevance of these models was evaluated by analyzing 
expression of several genes and proteins involved in the pathological mechanisms of these 
muscular dystrophies. Lastly, Ca2+ homeostasis was analyzed by intracellular Ca2+ imaging in 
these myotubes. In this line, in a previous study, our group has already reported abnormal 
calcium homeostasis in the LGMD2A in vitro model.
2. Materials and methods
2.1. Antibodies
Primary antibodies were obtained from the following sources: 12A2-Calpain3 (NCL-CALP-
12A2) (Leica Biosystems, Barcelona, Spain); Ryanodine Receptor type1 (MA3–925) (Affinity 
BioReagents, Golden, CO, USA); DHPRα2 (ab2864) (Abcam, Cambridge, UK); Actin (A2066), 
and Actinin (A7811) (Sigma-Aldrich, Madrid, Spain); Myosin Heavy Chain (MyHC A.1025) 
and Dystrophin (MANDYS1) (DSHB, Iowa City, IA, USA); Aldolase A (SC-12059) and 
α-sarcoglycan (SC-271321) (Santa Cruz Biotechnology, Heidelberg, Germany).
2.2. Culture conditions
LHCN-M2 immortalized human were generated in the Platform for Immortalization of 
Human Cells (Myology Institute, Paris, France), as previously described [35]. LHCN-M2 
myoblasts were grown in Skeletal Growth Medium (SGM, C-23060, Promocell, Heidelberg, 
Germany) on 12-mm coverslips (Thermo Scientific, Madrid, Spain) coated with 0.5% gelatin 
(G1890, Sigma-Aldrich). At confluence, cells were washed with Dulbecco’s phosphate-buffered 
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saline—DPBS (Life Technologies, Madrid, Spain) and 200 μl of Extracellular Matrix Gel 
(E6909, Sigma-Aldrich) diluted at 1:3 ratio in Dulbecco’s Modified Eagle’s Medium (41966-
029, Life Technologies) was added. Cultures were incubated at 37°C for 30 min in order 
to let extracellular matrix proteins self-assemble and produce a thin overlay of ~1 mm 
covering myoblasts. Then, differentiation medium was added to cultures (DM1, Table 1) 
and half of the medium was replaced every 3 days. In some experiments, a differentia-
tion medium with trophic factor was added to cultures (DM2, Table 1), when myoblasts 
started to fuse and form large multinucleated myotubes (at 3–4 days post-differentiation). 
See Figure 2A for schematics. Similar results were obtained with myoblasts grown in pro-
liferation medium (Table 1), instead of commercial SGM. Culture media reagents were 
obtained from the following sources: Fetal Bovine Serum (FBS, 10270-106), Newborn Calf 
Serum (NCS, 16010-159), GlutaMAX-I (35050-038), MEM (51200-038), Medium 199 (M199, 
31150-022), Neurobasal A medium (10888-022), B27 supplement (17504-44), mouse laminin 
(23017-015), bFGF (13256-029), and Gentamicin (15750-037) were from Life Technologies; 
human sonic hedgehog (Shh, 1845-SH-025), IGF-1 (4326-RG), CNTF (557-NT), and agrin 
(550-AG-100) were obtained from R&D Systems (Abingdon, UK); EGF (AF-100-15), BDNF 
Table 1. Culture media used for human myoblast growth and differentiation.
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(450-02), and NT-3 (450-03) from Peprotech (London, UK); insulin (I6634), human apo-
transferrin (T1147), Fetuin (F2379), HEPES (H3375), and dexamethasone (D2915) were 
obtained from Sigma-Aldrich.
2.3. Lentiviral infection
Lentiviral particles were produced by Inbiomed (San Sebastian, Spain) from plasmid DNAs 
TRCN0000003494 (shCapn3), TRCN0000053243 (shDyst) and SHC002 (NS-shRNA) (Sigma-
Aldrich). Human immortalized LHCN-M2 myoblasts were seeded at approximately 25% of 
confluence and the next day, cells were infected at MOI 5 with 4 μg/ml polybrene (H9268, 
Sigma-Aldrich). Myoblasts were selected and expanded in SGM with 1 μg/ml puromycin 
(A11138-03, Life Technologies) for 7 days, as previously described [36].
2.4. Western blot
Proteins from human myotubes grown on 24-well plates were lysed directly with 75 μl of 
reducing loading buffer and resolved in 4–20% gradient sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE) gels (Bio-rad, Madrid, Spain). A total of 10 μl of pro-
tein homogenates were loaded per lane, corresponding to ~10–15 μg of protein. Membranes 
were stained with Ponceau-S to verify similar total protein loaded. Proteins were transferred 
onto nitrocellulose membranes, blocked with 5% nonfat milk, and 2% goat serum (Sigma-
Aldrich) in Tris-buffered saline with 0.1% Tween 20 (TBST). Membranes were incubated with 
primary antibodies overnight at 4°C and the following day, membranes were washed and 
incubated with horseradish peroxidase-conjugated secondary antibodies diluted 1:40,000 
for 1 h (Santa Cruz Biotechnology). Chemiluminescent signal detection was performed with 
Supersignal West Dura kit (Thermo Scientific).
2.5. Immunocytochemistry
Myotubes grown onto 12-mm glass coverslips were fixed in acetone for 3 min. Cells were 
washed with phosphate-buffered saline (PBS) and preincubated for 1 h with 2% normal horse 
serum, 2% bovine serum albumin, and 0.5% Triton X-100 in PBS. Cells were incubated over-
night at 4°C with primary antibodies and then washed and incubated with Alexa Fluor 488-, 
CY3-, or CY5-conjugated secondary antibodies (1200, Life Technologies). Coverslips were 
mounted with Prolong Gold antifade reagent with 4′,6-diamidino-2-phenylindol (DAPI) (Life 
Technologies). Samples were visualized on an inverted epifluorescent microscope (Nikon 
Ti-S) and images were acquired with a high-resolution camera (ORCA Flash 2.8, Hamamatsu).
2.6. Myotube viability determination
Myotube viability was determined with the cytotoxicity assay Cytotox96 (Promega, Madrid, 
Spain), which quantifies lactate dehydrogenase (LDH) activity. Myoblasts were seeded in gel-
atin-coated 96-well plates, grown to confluence and differentiated. LDH was measured in 3–4 
replicates at several time points during the differentiation process, in both supernatants and 
cell lysates. For this assay, myotubes were directly lysed with 20 μl of 0.1% Triton X-100 in 
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2 M Tris solution. Myotube viability was calculated from the ratio between LDH released to 
the medium to total intracellular LDH in myotube lysates. Percentage of myotube viability at 
7 and 10 dpd was normalized to levels at 5 dpd (100%).
2.7. Myotube differentiation and maturation
Total creatine kinase (CK) activity has been previously used to determine levels of myo-
tube differentiation and maturation [37]. CK activity was determined with the colorimetric 
kit CK-NAC (Thermo Scientific) at several days during myotube differentiation. Cells were 
grown and differentiated in 96-well plates and directly lysed with 20 μl of 0.1% Tris 2 M 
Triton solution. Myotube differentiation levels were expressed as the fold increases in CK 
activity normalized to levels obtained at 3 dpd.
2.8. Total protein quantification
Total protein was quantified with Bradford protein assay (Bio-rad). Myotubes differentiating 
in 96 well plates were lysed with 20 μl of 0.1% Triton X-100 in 2 M Tris solution.
2.9. Calcium imaging
Myotubes grown on glass coverslips were loaded with 4 μM Fura 2-AM for 30 min at 
37°C. Cells were incubated in Ringer buffer (125 mM NaCl, 5 mM KCl, 6 mM glucose, 
2 mM CaCl
2
, 1.2 mM MgSO
4
 and 25 mM HEPES, pH 7.4) for 20 min at room temperature to 
remove non-hydrolyzed fluorophore and complete de-esterification of the dye. Experiments 
were performed at 37°C under continuous perfusion (2 ml/min) with Ringer buffer using an 
ECLIPSE Ti-S/L100 microscope (Nikon) equipped with a 20X S-Fluor objective and attached 
to a lambda-DG4 illumination system. Image acquisition was performed using an Orca-Flash 
2.8 camera (Hamamatsu) with the Nis-Elements AR software. Variations in Ca2+ levels over 
time are determined by the ratio between the fluorescence intensities at 340 and 380 nm exci-
tation wavelengths.
2.10. RT-qPCR
mRNA levels of CAPN3, GRP78, CHOP, HERP, X-box binding protein-1(XBP1), and 
spliced XBP1 (sXBP1) were quantified using complementary DNA (cDNA) synthesized 
from DNAse-treated RNA obtained from control (shCtrl) and Capn3-deficient LHCN-M2 
myotubes (shCapn3). qPCR was performed and analyzed with the 7900HT Real-Time 
PCR System (Applied Biosystems), using SyberGreen master mix as previously described 
[36, 38]. Measurements were performed in triplicates in three different cultures, and the 
results were normalized to a normalization factor based on the geometric mean of four 
reference genes: creatine kinase (CK), DHPRα1, dmd, and HPRT1. The primer sequences are 
shown in Table 2. Primers were designed using Primer Express software (Thermo Fisher), 
and specificity was ensured with reverse e-PCR online software (www.ncbi.nlm.nih.gov/
projects/e-pcr/reverse.cgi).
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2.11. Statistical analyses
Data are presented as mean ± SEM. An independent t-test with a significance level of 0.05 was 
applied to test differences between two groups. For multiple group comparisons, one-way 
analysis of variance (ANOVA) test was applied with Tukey’s post hoc test.
3. Results
3.1. Extracellular matrix overlay increases attachment and results in mature 
LHCN-M2 human myotubes
LHCN-M2 myoblasts were grown on gelatin-coated tissue culture plates and differentiated fol-
lowing standard protocols (see Section 2). Differentiation medium (DM1, Table 1) was added 
when myoblasts reached confluence, and at 3 days post-differentiation (dpd) first myotubes were 
observed. In our hands, detachment of myotubes started at 7 dpd and almost no myotubes survived 
after 10 dpd (Figure 1). Among different cultures, a substantial variability in myotube survival 
and differentiation was observed within this period. We hypothesized that myotube maturation 
was hindered by deficient attachment and, thus, we aimed to  optimize myotube attachment by 
Table 2. Primers sequences used for qPCR experiments.
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addition of a suitable protein scaffold. We analyzed the effect of extracellular matrix gel (ECM) 
on myotube attachment, since previous studies have indicated that addition of ECM proteins to 
human myotubes facilitates muscle cell attachment and organization [39]. Also, we anticipated 
that enriching extracellular architecture would provide additional support during myotube con-
traction. Thus, an ECM gel secreted by Engelbreth-Holm-Swarm mouse sarcoma cells was added 
to myotube cultures in order to provide both protein components and a suitable scaffold. Several 
dilutions and protocols were tested, and best results were obtained with a 1-mm layer of ECM 
gel diluted 1:3 in Dulbecco’s Modified Eagle’s Medium, which was added to confluent myoblasts 
(see Section 2). Similar improvements in myotube attachment, survival, and maturation were 
observed using the analogous protein mixture BD Matrigel Basement Membrane Matrix diluted 
1:3 (data not shown). Specifically, we found that addition of an ECM overlay to myoblasts 
Figure 1. Addition of an extracellular matrix overlay enhances human LHCN-M2 myotubes survival and maturation. 
(A) Representative bright field images of myotubes at several days post-differentiation (1–7 dpd) in standard culture 
conditions (upper row) or differentiated under a ~1 mm ECM overlay (lower row). (B) Western blot analysis of skeletal 
muscle differentiation markers (1–7 dpd) under standard conditions (left panel) and with an ECM overlay (right panel). 
(C) Quantification of myotube differentiation levels, expressed as average fold increase in creatine kinase (CK) activity. 
Addition of an ECM overlay (white circles) before differentiation resulted in a significant increase in myotube maturation 
levels compared to standard condition (black circles). (D) Myotube viability was quantified at 5, 7, and 10 dpd. Addition 
of an ECM overlay (white circles) resulted in a significant increase in myotube viability compared to standard condition 
(black circles). ECM overlays promoted attachment and survival of myotubes beyond 10 dpd. All data expressed as 
mean ± SEM, n = 4 *p < 0.05, **p < 0.005). ECM, extracellular matrix gel; dpd, days post differentiation. Scale bar = 40 μm.
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significantly extends the culture lifetime, promoting development of mature striated myotubes 
that survive for up to 12–14 dpd (Figure 2). In addition, we often observed spontaneous contractile 
activity in cultures with the longest lifetimes (Video 1, https://www.intechopen.com/download/
index/process/151/authkey/84bcd15620efa9dacbd8d3c504b4f45a). Analysis of specific skeletal 
muscle proteins by Western blot revealed that compared to standard culture conditions, myotubes 
differentiated under ECM overlays display higher levels of dystrophin, calpain 3, and myosin 
heavy chain (MyHC, Figure 1B), and expression of these proteins was detected at earlier stages 
of differentiation. Effect of ECM overlays on human myotube differentiation was quantified by 
measuring the increase in creatine kinase (CK) enzyme activity, which is a sensitive marker of dif-
ferentiation [37]. We found that addition of an ECM overlay to confluent myoblasts significantly 
increased CK activity at both 5 and 7 dpd (Figure 1C; p < 0.05). Finally, effect of ECM overlays on 
myotube survival was quantified at 5, 7, and 10 dpd by measuring lactate dehydrogenase (LDH) 
released to the medium from dying myotubes. We found that addition of an ECM overlay signifi-
cantly increased cell viability at 7 dpd compared to standard conditions (p < 0.05). At 10 dpd, most 
of the myotubes are detached in standard cultures, whereas myotubes differentiated under ECM 
overlays retained ~80% cell viability compared to levels at 5 dpd (100%; p < 0.001, Figure 1D). 
These data support our theory that providing an appropriate protein scaffold to human myotube 
cultures results in higher attachment and survival and, as a consequence, it produces a signifi-
cant increase in the maturation levels of these myotubes, which develop spontaneous contractile 
capacity.
3.2. Optimization of differentiation medium to further improve survival and 
maturation of human myotubes
Presence of trophic factors during differentiation may further stimulate maturation of 
LHCN-M2 human myotubes, as previously reported for primary human myoblasts [22]. 
Therefore, we designed a new differentiation medium that included several factors with 
reported activity for promoting myotube survival and maturation, such as agrin and neuro-
trophins [16, 40]. This new differentiation medium (DM2, Table 1) was added to myotubes 
cultured under ECM overlays when large myotubes first appeared, which was usually at 
3–4 dpd (Figure 2A for schematics). A few days after DM2 addition, there was an obvious 
increase in myotube density compared to myotubes differentiated in DM1 (Figure 2B, 7–9 
dpd). This was confirmed by total protein content quantification, which revealed significant 
2- to 3-fold increases at 5, 7, and 10 dpd in myotube cultures differentiated in DM2 compared 
to DM1 (Figure 2C). Around 12–14 dpd, most of the myotubes differentiated in DM2 pre-
dominantly displayed a rhythmic and vigorous contractile activity and myotube lifetime was 
usually extended beyond 15 dpd (Video 2, https://www.intechopen.com/download/index/
process/151/authkey/84bcd15620efa9dacbd8d3c504b4f45a). Moreover, most myotubes differ-
entiated in DM2 displayed well-defined sarcomeric patterns and peripherally aligned nuclei 
at 14 dpd (Figure 2B). Next, we analyzed the developmental expression profiles for a range 
of myogenic proteins throughout myotube differentiation in both media (Figure 2D). Overall, 
myotubes differentiated in DM2 showed higher maturation as observed by higher expression 
levels of dihydropyridine receptor (DHPR), ryanodine receptor 1 (RyR1), and MyHC. This 
was supported by significantly higher CK activity levels in myotubes differentiated in DM2 
compared to DM1, at 10 dpd and beyond (Figure 2E). Finally, quantification of released LDH 
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Figure 2. Differentiation medium with trophic factors further increases LHCN-M2 myotubes density, survival, and 
maturation. (A) Schematics of the optimized differentiation protocol. Human LHCN-M2 myoblasts were seeded onto 
gelatin-coated coverslips and grown until confluence. Medium was removed and 200 μl of ECM (1:3 dilution) was 
added over myoblasts. A gel scaffold was allowed to form by incubating 30 min at 37°C. Myoblasts were differentiated 
in standard differentiation medium (DM1) until multinucleated myotubes emerged (around 3–4 dpd). Then, this 
medium was substituted by a differentiation medium with trophic factors (DM2). At 10–14 dpd, mature, cross-striated, 
and contractile myotubes were observed. (B) Representative bright field images of LHCN-M2 myotubes differentiating 
under ECM overlay. Upper row images represent myotubes differentiating in standard medium, while lower row 
images depict myotubes where DM2 differentiation medium was added at 3 dpd. (C) Protein quantification from 
myotubes differentiating under ECM overlays at 5, 7, and 10 dpd. DM2 differentiation medium (black bars) promoted a 
significant increase of protein content compared to standard medium (white bars). (D) Western blot analysis of several 
myogenic proteins shows higher maturation of myotubes differentiating under ECM overlay with DM2 (right) compared 
to standard medium (left). (E) Addition of DM2 significantly increased myotube maturation levels, as expressed as 
average fold increase in creatine kinase (CK). (F) Addition of DM2 significantly increased myotube viability. At 14 dpd, 
viability of myotubes differentiated in DM2 was preserved (white circles), while it was markedly reduced in myotubes 
differentiated in standard medium (black circles). Data are expressed as mean ± SEM, n = 4 *p < 0.05, **p < 0.005. Scale 
bar = 40 μm; 5 μm in inset. DM2, differentiation medium 2; dpd, days post differentiation.
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showed that myotubes cultured in DM2 displayed significantly higher viability levels than 
the ones in DM1 (Figure 2F). These results demonstrate that among the different conditions 
analyzed in this study, the combination of ECM overlays and DM2 medium constitute the 
most suitable environmental conditions for the generation of highly mature and functional 
human myotubes with a more extended lifetime.
3.3. Silencing gene expression in highly mature LHCN-M2 myotubes as a relevant 
human model of muscular dystrophies
We aimed to generate relevant human cellular models of muscular dystrophies by silenc-
ing specific proteins in LHCN-M2 myoblasts in combination with the optimized myo-
tube differentiation protocol described earlier. Thus, we used lentivirus carrying short 
hairpin RNAs (shRNAs) specific for human calpain 3 (shCapn3) or dystrophin (shDyst), 
in order to generate cellular models of limb-girdle muscular dystrophy type 2A (LGMD2A) 
and Duchenne muscular dystrophy (DMD), respectively. Myoblasts infected with lentivirus 
carrying none-silencing shRNAs were used as controls (shCtrl). Infected LHCN-M2 myo-
blasts were selected with puromycin for more than 10 days and resistant myoblasts were 
expanded and used for subsequent analyses after verification of knockdown efficiency. We 
noticed that when compared to noninfected LHCN-M2 myoblasts, those subjected to lentivi-
rus infection and subsequent selection resulted in myotubes with a reduced contractile capac-
ity, although a number of myotubes with spontaneous contractility were observed.
We found that lifetime of shCtrl and shCapn3 myotubes extended up to 14 dpd, whereas 
shDyst myotubes showed obvious early detachment, and they were unable to survive beyond 
12 dpd (Figure 3A). Quantification of myotube viability by measuring released LDH con-
firmed that viability of shDyst myotubes was significantly diminished at 11 dpd compared 
to shCtrl myotubes (68.13 ± 3.65 vs. 97.66 ± 1.20%; p < 0.005). In contrast, viability of shCapn3 
myotubes (97.00 ± 1.03% at 11 dpd) did not show any difference compared to controls through-
out differentiation (Figure 3B). Also, no obvious differences in myotube maturation levels 
were observed between control (shCtl) and dystrophic myotubes (shDyst and shCapn3), as 
quantified by fold increase in CK activity (Figure 3C). Likewise, no marked differences in cell 
morphology were observed between dystrophic and control myotubes (Figure 3A).
We have already reported a preliminary characterization of our LGMD2A model in a recent 
study [36]. In summary, we achieved an efficient silencing of Capn3 expression in human 
myotubes that resulted in a concomitant reduction of sarco/endoplasmic reticulum Ca2+-
ATPase and RyR1 protein levels (Figure 4A). Thus, our results are in line with previous stud-
ies showing that SERCAs and RyR1 protein levels undergo significant reduction in mouse 
models [36, 41] as well as in muscle samples from LMGD2A patients [36, 42]. Furthermore, 
we have found that the expression of the antiapoptotic factor cellular FLICE (FADD-like 
IL-1β-converting enzyme)-inhibitory protein (c-FLIP), was downregulated by 25% in Capn3-
deficient myotubes. This result supports a previous study performed in LGMD2A biopsies 
claiming that c-FLIP expression is regulated by Capn3 via NF-κβ signaling [43]. Since the 
Capn3-deficient cellular model displays multiple alterations of sarcoplasmic reticulum (SR) 
homeostasis such as reduction of SERCA and RyR1 proteins, as well as abnormal calcium 
homeostasis, we next sought to determine whether SR-stress pathways were upregulated in 
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Figure 3. Generation of human cellular models of muscular dystrophies by shRNA lentiviral transduction. (A) 
Representative bright field images of LHCN-M2 myotubes infected with lentivirus-carrying control non-silencing 
(shCtrl), dystrophin (shDyst), or calpain 3 (shCapn3) shRNAs, at 6, 9, and 11 dpd. At 11 dpd, obvious detachment of 
shDyst expressing myotubes was observed. (B) At 11 dpd, viability of shDyst expressing myotubes (white circles) was 
significantly reduced to 60% as opposed to shCtrl (black circles) or shCapn3 (gray triangles) expressing myotubes, which 
showed no obvious decrease in their viability. (C) Similar maturation levels were observed among myotubes expressing 
shCtrl, shDyst, or shCapn3 throughout 11 days of differentiation, as quantified by fold increase in creatine kinase (CK) 
activity. Data expressed as mean ± SEM, n = 3 *p < 0.05, **p < 0.005). Scale bar = 40 μm.
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Figure 4. Validation of the human cellular models for muscular dystrophies. (A) Western blot analysis in LHCN-M2 
myotubes expressing control non-silencing shRNA (shCtrl) and calpain 3 shRNA (shCapn3). Efficient silencing 
of calpain 3 expression was confirmed in shCapn3 myotubes. Compared to controls, calpain 3-deficient myotubes 
displayed a concomitant reduction of SERCA and RyR1 protein levels, while MyHC and actin levels remained 
unchanged. (B) Analysis of mRNA expression levels in the LGMD2A model. CAPN3, c-FLIP, and several genes 
involved in sarcoplasmic reticulum stress (CHOP, GRP78, HERP, and XBP1) in the LGMD2A model. Calpain 3-deficient 
myotubes present a concomitant decrease of c-FLIP mRNA levels. Compared to controls, shCapn3 myotubes show 
increased mRNA levels of several genes associated with sarcoplasmic reticulum stress, such as CHOP, HERP, GRP78, 
and the spliced XBP1/XBP1 ration. (C) Western blot analysis in LHCN-M2 myotubes expressing control non-silencing 
shRNA (shCtrl) and dystrophin shRNA (shDyst). Efficient silencing of dystrophin expression was confirmed in shDyst 
myotubes. Compared to controls, shDyst myotubes displayed a reduction of α-sarcoglycan, while levels of MyHC 
and DHPRα2 remained unchanged. (D) Double immunostaining of α-actinin (red) and dystrophin (green) in control 
(shCtrl) and dystrophin knockdown (shDyst) myotubes. Scale bar = 10 μm. (E) Resting intracellular Ca2+ levels of control 
(shCtrl), calpain-deficient (shCapn3), and dystrophin-deficient (shDyst) myotubes were measured with ratiometric dye 
Fura-2 AM. Left: Representative pseudocolored images showing the F340/F380 fluorescence ratio recordings. Right: 
Quantification analysis shows that both dystrophic models, shCapn3 (142 ± 11%) and shDyst myotubes (158 ± 17%), 
present significantly higher resting intracellular calcium levels than controls (100 ± 8%). Data expressed as mean ± SEM. 
200–500 myotubes were analyzed from at least N = 3 independent experiments; *p < 0.05 vs. shCtrl. Scale bar = 25 μm.
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our model. Indeed, we observed overexpression of SR-stress-related genes such as GRP78, 
CHOP, HERP, and spliced XBP1 in shCapn3 myotubes (Figure 4B) [44–46]. SR stress leads 
to the activation of the unfolded protein response (UPR), which involves splicing of X-box 
binding protein-1 (XBP1) mRNA. After sustained UPR, the transcriptional factor CCAAT/-
enhancer-binding protein homologous protein is induced, which leads to caspase activation 
and apoptosis [47]. Our results indicate that Capn3 deficiency results in significant SR stress 
that leads to activation of programmed cell death, which is likely caused by reduced protein 
levels of RyR1 and SERCAs. Therefore, skeletal muscle fiber apoptosis due to SR stress may 
be a crucial event in the pathological mechanism of LGMD2A patients.
In the DMD model, we verified efficient knockdown of dystrophin in shDyst myotubes by 
Western blot and immunocytochemistry (Figure 4C and D). Immunocytochemical analysis 
revealed a predominant sarcolemmal distribution of dystrophin in shCtrl myotubes, which is 
indicative of high maturation of myotube cultures. As expected, dystrophin was mostly unde-
tectable in shDyst myotubes (Figure 4C and D). Next, we sought to assess expression levels 
of α-sarcoglycan, a member of the dystrophin-dystroglycan complex, since this protein has 
been repeatedly found diminished in muscle biopsies from patients with Duchenne muscular 
dystrophy [48–50]. Consistent with these reports, we found that shDyst myotubes display a 
marked reduction of α-sarcoglycan levels compared to shCtrl myotubes (Figure 4C).
Finally, we sought to analyze Ca2+ homeostasis capacity of dystrophic myotubes, since sev-
eral studies have shown that calcium dysregulation is involved in several forms of muscular 
dystrophy [51]. Indeed, as we have previously reported [52], resting intracellular calcium 
levels were significantly increased in Capn3-deficient myotubes by 42% compared to control 
myotubes (Figure 4E). Interestingly, we observed an even higher increase in the resting cyto-
solic calcium levels of shDyst myotubes (by 58%) compared to control myotubes. Overall, our 
findings regarding Ca2+ homeostasis and expression/localization of proteins involved in the 
pathological mechanisms of muscular dystrophies indicate that our human cellular models 
are suitable for the study of these muscular disorders, and they may be particularly helpful as 
a drug-screening platform for compounds targeting calcium homeostasis.
4. Discussion and conclusions
In this work, we present a novel tool for the study of muscular dystrophies and other genetic 
muscle disorders, which is based on the previously described human immortalized myoblast cell 
line LHCN-M2 [35]. This is a well-characterized and widely used human myogenic cell line that 
displays a similar in vivo and in vitro behavior to the one observed in primary myoblasts [52–55].
Since most of the relevant proteins involved in the pathogenesis of muscular dystrophies are 
expressed at late stages of myogenic differentiation, first we optimized culture conditions of 
LHCN-M2 cells to achieve highest levels of myotube maturation and survival. This protocol 
could also be suitable for other human cell lines as well as for primary human myoblasts. 
Furthermore, we have generated human cellular models of LGMD2A and Duchenne mus-
cular dystrophies by combining these culture conditions with long-term gene silencing of 
calpain 3 and dystrophin in LHCN-M2 myoblasts. Compared to previous in vitro human 
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systems, our model is inexpensive, straightforward, and does not require special equipment. 
In addition, it overcomes several limitations of other human in vitro models such as sample 
availability, heterogeneity among different samples, and lack of physiological relevance. In 
this regard, our cellular models display several features characteristic of muscles from patients 
with muscular dystrophies, which validates their relevance to these disorders. In addition, as 
shown here, as well as in our previous study [36], the high maturity of these myotube cultures 
allows for localization analysis of proteins involved in the pathogenesis of muscular dystro-
phies as well as calcium transients recording. Our results regarding generation of highly dif-
ferentiated human myotubes are consistent with a previous study describing human satellite 
cell differentiation under serum-free culture conditions [22]. Indeed, both procedures accom-
plish highly mature human myotubes capable of spontaneous contraction without neural 
innervation. However, our model has several advantages over previous methods. First, the 
use of the LHCN-M2 cell line allows for unlimited sample and higher homogeneity among 
experiments, since human primary myoblasts or satellite cells display a wide heterogeneity 
in terms of proliferation capacity and fusion into myotubes [56]. Also, substantial differences 
in human myotube survival and response to extrinsic factors have been observed among 
primary cultures from different samples [6]. Cellular senescence is an additional limitation 
of human primary myoblasts, which typically restricts in vitro myoblast proliferation to a 
maximum of 15–20 divisions. In addition, this proliferative potential decreases dramatically 
in dystrophic conditions such as Duchenne muscular dystrophy [7, 57].
As additional advantages of our model, instead of complex polymeric coatings or micro-pat-
terned surfaces [22–25], we use a simple overlay of ECM gel to provide a suitable scaffold 
that results in increased myotube attachment, maturation, and survival. In fact, addition of 
this scaffold is sufficient to induce contraction capability in LHCN-M2 myotubes, without 
the need of neural innervation or addition of trophic factors. However, when an optimized 
differentiation medium with trophic factor was added to ECM overlaid cultures, contractile 
capacity displayed by myotubes was notably widespread throughout the whole culture.
Once myotube differentiation was optimized, shRNA-lentiviral infection was performed in 
order to silence expression of proteins relevant to muscular dystrophies. In particular, we 
accomplished efficient long-term knockdown of calpain 3 and dystrophin in LHCN-M2 
myotubes, whose deficiency in skeletal muscle cause, respectively, Duchenne and LGMD2A 
muscular dystrophies. Remarkably, these proteins are expressed at late stages of myotube 
differentiation, so highly mature myotubes are essential to study deficiency of these proteins. 
While infected myotubes did not display a widespread contractile capacity as the one shown 
by noninfected myotubes, high maturation levels were demonstrated in both control and 
dystrophic myotubes by the presence of a striated actinin pattern. Most importantly, calpain 
3 and dystrophin-deficient LHCN-M2 myotubes recapitulate key features of LGMD2A and 
Duchenne muscular dystrophies, such as reduced expression and abnormal localization of 
several proteins involved in their pathological mechanisms. In particular, dystrophin-deficient 
myotubes differentially showed reduced attachment, likely due to dystrophin’s main func-
tion as an anchor between extracellular matrix and the contractile apparatus [58]. Overall, our 
findings validate the relevance of our novel in vitro human muscle model to LGMD2A and 
Duchenne muscular dystrophies. In addition, maturation of the cellular model may be further 
enhanced, if needed, with chronic electrical stimulation, as reported in previous works [12, 13].
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Current research is focusing on novel therapeutic strategies for muscular disorders, but there 
is an obvious lack of appropriate in vitro human models to test these strategies. Animal models 
are often used for in vivo preclinical testing before moving forward to clinical trials. However, 
many examples in the literature indicate that therapies tested on animals may not necessarily 
yield the same outcomes in humans. Our novel human cellular model of muscular dystro-
phies described in this study allows testing of new therapies and treatments in a system more 
representative of human muscle pathologies, which may be used to complement preclinical 
studies performed in animal models. While this model has been validated for muscular dys-
trophies, we expect that the methodology described in this work could be also applicable to 
primary or immortalized human myoblasts to study other muscle disorders.
In conclusion, here we present a relevant human in vitro system that offers multiple possibilities 
for the study of skeletal muscle pathophysiology. Our model could be easily adapted to obtain 
cellular models for other neuromuscular diseases, and it may be further customized using cur-
rent technological advancements in genomic editing (transcription activator-like effector nucle-
ases—transcription activator-like effector nucleases (TALEN), Clustered Regularly Interspaced 
Short Palindromic Repeats/CRISPR associated protein 9 (CRISPR/Cas9)), exon skipping or 3D 
tissue engineering in order to generate more refined in vitro muscle models. Low variability of 
the system would allow its use for high throughput screening of potential therapeutic drugs for 
muscular diseases, with an emphasis on compounds targeting calcium homeostasis.
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